Inventiva is focused on developing differentiated treatments for MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease), with a commitment to scientific excellence and patient urgency
Inventiva is focused on developing differentiated treatments for MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease), with a commitment to scientific excellence and patient urgency. Their lead product candidate, lanifibranor, is currently in clinical development and has received FDA Breakthrough Therapy Designation.